ACTRIMS: Americas Committee for Treatment and Research in Multiple Sclerosis

Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.

Ari Green, MD, University of California, San Francisco, discusses the promising results observed in current remyelination trials in multiple sclerosis (MS) and the patient-specific features that may influence therapy outcomes.

Mitzi Joi Williams, MD, of Joi Life Wellness Multiple Sclerosis (MS) Center, lists challenges in recruiting and retaining minority populations for clinical trials and discusses ways to ensure clinical trial accessibility.

Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.

Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University's Meinig School of Biomedical Engineering, discusses using engineered 3D platforms to identify potential multiple sclerosis (MS) drug candidates.

While the results of evolutionRMS, comparing evobrutinib with teriflunomide, were negative, that "doesn't mean that evobrutinib is not working," said Xavier Montalban, MD, PhD, director of the Multiple Sclerosis Center of Catalonia (Cemcat).

Ateyeh Soroush, a PhD candidate at the University of Calgary, explains her ongoing study utilizing near-infrared spectroscopy (NIRS) to investigate hypoxia-related brain function impairment in patients with multiple sclerosis (MS).

The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence (AI) in research and treatment approaches in multiple sclerosis (MS).

Speakers on the final day of the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 discussed advancements in rehabilitation trials in multiple sclerosis (MS) and unmet research needs.

Ari Green, MD, of the University of California, San Francisco, details the benefits of remyelination for patients with multiple sclerosis (MS), as well as the challenges faced when conducting remyelination trials.

Mitzi Joi Williams, MD, founder and medical director of Joi Life Wellness Multiple Sclerosis (MS) Center, explains the issue of underrepresentation in MS clinical trials and the potential for digital health technologies to help overcome this barrier.

Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University, discusses MS drug discovery barriers and overcoming them using 3D platforms.

Young investigators spoke to emerging metabolic and cognitive research in multiple sclerosis (MS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.

Dalia Rotstein, MD, MPH, assistant professor of medicine at the University of Toronto, lists barriers to multiple sclerosis (MS) research and care delivery.

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 opened with discussions on the novel concepts emerging in multiple sclerosis (MS) research, such as the associations between synaptic loss and hypoxia with disease progression.

Marisa McGinley, DO, explains how technology can help improve access to multiple sclerosis (MS) care.

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a plethora of barriers faced by patients and clinicians managing multiple sclerosis (MS).

Daniel Ontaneda, MD, PhD, Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 chair, discussed what attendees can expect at this year's meeting, as well as how the theme of "Breaking Barriers in MS" will be implemented.